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A sensitive method based on high-performance liquid chromatography–tandem mass spectrometry (LC–
MS/MS) has been developed for the simultaneous determination of folic acid (FA) and its active meta-
bolite, 5-methyltetrahydrofolic acid (5-M-THF), in human plasma. The analytes were extracted from
plasma with methanol solution containing 10 mg/mL of 2-mercaptoethanol and 0.025% (v/v) ammonium
hydroxide. FA and 5-M-THF were more stable after the addition of 2-mercaptoethanol and ammonium
hydroxide in the sample preparation procedures of this study than they were in the previously published
methods. Chromatographic separation was performed on a Hedera ODS-2 column using a gradient
elution system of acetonitrile and 1 mM ammonium acetate buffer solution containing 0.6% formic acid
as mobile phase. LC–MS/MS was carried out with an ESI ion-source and operated in the multiple reaction
monitoring (MRM) mode. The assay was linear over the concentration ranges of 0.249–19.9 ng/mL for FA,
and 5.05–50.5 ng/mL for 5-M-THF. The developed LC–MS/MS method offers increased sensitivity for
quantiﬁcation of FA and 5-M-THF in human plasma and was applicable to a pharmacokinetic study of FA
and 5-M-THF.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Folates belong to B vitamins and are essential elements in the
diet. They are a group of compounds derived from food-stuffs. The
key folate forms include folic acid (FA), 5-methyltetrahydrofolic
acid (5-M-THF), 5-formyltetrahydrofolate, 5,10-methenyltetrahy-
drofolate, S-adenosylmethionine, and S-adenosylhomocysteine
[1]. Previous studies showed that folate deﬁciency was associated
with increased risk of neural tube defects [2,3], coronary heart
disease [4,5], certain types of cancer [6,7], Down's syndrome [8],
and red-cell aplasia [9]. Nowadays FA is used as an oral supple-
ment by patients with these disorders and recommended to wo-
men of childbearing age to reduce the risk of neural tube defects.
FA is absorbed in the small intestine and is reduced to theon and hosting by Elsevier B.V. All
University.metabolically active tetrahydrofolate forms inside the cells. 5-M-
THF is the most predominant active metabolite, which accounts
for approximately 98% of folates in human plasma [10].
The structures of FA and 5-M-THF are shown in Fig. 1. The main
challenge in FA and 5-M-THF quantiﬁcation is their instability due
to the cleavage of the C9–N10 covalent bond and the reduction of
the pterin ring [11], because they are easily degraded under dif-
ferent conditions of temperature [12], pH [12,13], oxygen [14] or
light [15]. Just as early research reports, FA and 5-M-THF are more
stable in alkaline conditions than in acidic conditions [16].
Folates in human serum and plasma have been measured by
various chromatographic methods, including high performance
liquid chromatography (HPLC) [17], liquid chromatography–mass
spectrometry (LC–MS) [18], and liquid chromatography–tandem
mass spectrometry (LC–MS/MS) [1,19–24]. However, these meth-
ods were not all convenient for routine analysis due to various
reasons such as employing large sample volumes [19], having long
retention time [21] or applying time-consuming extraction pro-
cedures (puriﬁed by folate binding protein afﬁnity columns[19] or
solid-phase extraction (SPE) [21–24]). Moreover, these reports did
not put emphasis on the stability of FA and 5-M-THF during therights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Chemical structures of (A) FA, (B) 5-M-THF and (C) IS and their proposed
fragmentation patterns.
Fig. 2. The degradation of (A) FA (9.95 ng/mL) and (B) 5-M-THF (20.2 ng/mL) in
plasma at different concentration levels of 2-mercaptoethanol at room
temperature.
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reproducible LC–MS/MS method for the simultaneous quantiﬁca-
tion of FA and 5-M-THF in human plasma and it has been applied
to the pharmacokinetic study of FA and 5-M-THF in healthy Chi-
nese male volunteers.2. Materials and methods
2.1. Chemicals and reagents
The reference standard of FA (89.7%) was purchased from the
National Institute for Food and Drug Control (Beijing, China), re-
ference standard of moxonidine (99.2%) was obtained from the
National Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China), and reference standard of 5-M-THF
(98.1%) was supplied by Toronto Research Chemical Inc. (Ontario,
Canada). Acetonitrile and methanol were of gradient grade for li-
quid chromatography (Merck, Germany). Formic acid, ammonium
hydroxide and ammonium acetate were of analytical grade purity
and were purchased from Nanjing Chemical Reagent Co., Ltd.
(Nanjing, China). 2-Mercaptoethanol was purchased from Shang-
hai Sigma Metals, Inc. (Shanghai, China). FA tablets containing
5 mg of FA were purchased from Jiangsu Yabang Epson Pharma-
ceutical Co., Ltd. (Yancheng, China) and FA tablets containing
0.4 mg of FA were purchased from Beijing Slaine Pharmaceutical
Co., Ltd. (Beijing, China).2.2. Instrumentation and chromatographic conditions
The liquid chromatography was performed on an Agilent 1200
Series liquid chromatography (Agilent Technologies, Palo Alto, CA,
USA), which comprised an Agilent 1200 binary pump (model
G1312B), a vacuum degasser (model G1322A), an Agilent 1200
autosampler (model G1367C), and a temperature controlled col-
umn compartment (model G1330B). The chromatographic se-
paration was carried out on a Hedera ODS-2 analytical column
(150 mm2.1 mm i.d, 5 μm; Hanbon Science and Technology,
Huaian, Jiangsu, China) with a security guard C18 column
(4 mm2.0 mm i.d., 5 μm; Phenomenex, Torrance, CA, USA) at
the temperature of 38 °C.
The mobile phase consisted of acetonitrile (solvent A) and
1 mM ammonium acetate buffer solution containing 0.6% formic
acid (solvent B) was delivered at 0.40 mL/min according to the
following programs: 0–0.8 min (89% B), 1.0–2.0 min (30% B), 2.2–
5.0 min (10% B), and 5.2–10.0 min (89% B). The column efﬂuent
was directed into the mass spectrometer at the time interval of 0–
4.0 min, otherwise to waste. Autosampler temperature was
maintained at 4 °C and an injection volume of 8 μL was used in
each run.
The LC system was coupled with an Agilent 6410B triple
quadrupole mass spectrometer (Agilent Technologies, Palo Alto,
CA, USA) equipped with an electrospray source (model G1956B).
The electrospray ionization source was set with a drying nitrogen
gas ﬂow of 12 L/min, nebulizer pressure of 40 psig, drying gas
temperature of 350 °C, capillary voltage of 4.0 kV in positive ion
mode. The fragmentor voltages for FA, 5-M-THF and IS were 90,
105 and 100 V, respectively. The fragmentation transitions for the
multiple reaction monitoring (MRM) were m/z 442.2-295.2 for
FA with a collision energy (CE) of 22 eV,m/z 460.2-313.3 for 5-M-
THF with a CE of 20 eV, and m/z 242.1-206.1 for IS with a CE of
Fig. 3. Typical chromatograms of (A) blank plasma; (B) LLOQ for FA (0.249 ng/mL),
5-M-THF (5.05 ng/mL) and IS in plasma; and (C) plasma obtained from a volunteer
at 1.5 h after an oral administration of 0.8 mg folic acid.
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their proposed fragmentation patterns are presented in Fig. 1.2.3. Preparation of calibration standards and quality control samples
All FA and 5-M-THF standard solutions were prepared under
dim light to protect them from oxidative degradation by light.
Stock solutions of FA (497 μg/mL) and 5-M-THF (505 μg/mL) wereprepared in methanol: 5 mM of ammonium acetate solution
(50:50, v/v) containing 10 mg/mL of 2-mercaptoethanol and di-
luted with the same solution to make a series of standard working
solutions of 4.98, 9.95, 39.8, 99.5, 199, 298 and 398 ng/mL for FA
and 101, 202, 303, 404, 606, 808 and 1010 ng/mL for 5-M-THF.
Seven mixed calibration standard samples were then prepared
by spiking 500 μL of blank human plasma with 25 μL of working
solutions to give respective ﬁnal concentrations of 0.249, 0.498,
1.99, 4.98, 9.95, 14.9 and 19.9 ng/mL for FA and 5.05, 10.1, 15.2, 20.2,
30.3, 40.4 and 50.5 ng/mL for 5-M-THF. Three mixed quality con-
trol (QC) samples at three concentration levels (low: 0.595 ng/mL
for FA and 12.1 ng/mL for 5-M-THF; medium: 2.98 ng/mL for FA
and 21.2 ng/mL for 5-M-THF; high: 15.9 ng/mL for FA and
42.4 ng/mL for 5-M-THF) were prepared independently in the
same way. The IS working solution with the concentration of
50.2 ng/mL was prepared in methanol. All standard solutions and
plasma samples were stored at 80 °C until use.
2.4. Sample preparation
To an aliquot of 500 μL of human plasma (containing
100 μg/mL of 2-mercaptoethanol), 25 μL IS working solution
(50.2 ng/mL) was added and mixed for 10 s. The mixture was de-
proteinized with 1.5 mL of methanol solution containing
10 mg/mL of 2-mercaptoethanol and 0.025% (v/v) ammonium
hydroxide. After vortex for 3 min and centrifuged at 2005g for
10 min, the supernatant was transferred to a clean tube and eva-
porated under a stream of nitrogen gas in a water-bath of 35 °C to
dryness. The residue was immediately reconstituted in 150 μL of
acetonitrile – 5 mM of ammonium acetate buffer solution (11:89,
v/v) containing 10 mg/mL 2-mercaptoethanol. After vortex for
3 min, the reconstituted solution was transferred to a 1.5 mL Ep-
pendorf tube and centrifuged at 17024 g for 10 min. An 8 μL of the
supernatant was injected into the LC–MS/MS system for analysis.
The whole sample preparation process was carried out under a
dim light condition.
2.5. Method validation
Assay validation was performed according to FDA guidelines
[25].
Selectivity was performed using six different batches of blank
human plasma. Each blank sample should be tested for no other
endogenous components interference at the retention time of FA
and 5-M-THF except the endogenous FA and 5-M-THF and no
endogenous components interference at the retention time of IS.
FA and 5-M-THF are both endogenous substances in human
plasma, so their baseline levels in the blank plasma should be
subtracted from the calibration plasma samples before construct-
ing the calibration curves. We calculated the peak area ratio (f ) of
FA and 5-M-THF (As) to that of the internal standard (Ai), f¼As/Ai,
in calibration plasma samples. The obtained peak area ratio of the
blank plasma was deﬁned as fBK. The adjusted peak area ratio of
the calibration samples was deﬁned as f’, f’¼ f fBK. Calibration
curves of FA and 5-M-THF were respectively constructed by plot-
ting the f’ values against the amount added to the blank samples
and were calculated using linear regression analysis with 1/x2
weighing.
Accuracy and precision were evaluated according to Ref. [26].
Five replicate QC samples at three concentration levels were
analyzed on the same day and on three consecutive days in three
analytical batches using calibration curves established daily. The
precision at each concentration level was expressed as relative
standard deviation (%RSD) and accuracy as relative error (%RE).
The intra- and inter-day precision (%RSD) should not exceed 15%
and the accuracy (%RE) should be within 715%. Lower limit of
Table 1
Precision and accuracy for the analytes in human plasma (n¼20, 5 replicates per day for 3 days).
Analyte Nominal concentration
(ng/mL)
Intra-day Inter-day
Measured concentration
(ng/mL)
Precision
(%RSD)
Accuracy
(%RE)
Measured concentration
(ng/mL)
Precision
(%RSD)
Accuracy
(%RE)
FA 0.249 0.266 70.019 7.6 6.9 0.26670.019 3.8 7.0
0.595 0.63970.025 5.0 7.3 0.62770.033 6.6 5.3
2.98 2.9570.17 6.8 0.9 3.0170.19 4.5 1.0
15.9 16.070.7 4.7 0.5 16.270.8 8.8 1.8
5-M-THF 5.05 4.6470.56 9.4 8.1 4.9570.56 8.8 1.9
12.1 13.170.2 3.1 8.1 13.270.43 4.0 8.9
21.2 22.870.7 3.6 7.4 22.770.8 3.1 6.9
42.4 46.270.9 2.9 8.9 45.571.9 8.4 7.2
RSD: relative standard deviation.
RE: relative error.
Table 2
Extraction recovery and matrix effects for the analytes in human plasma (n¼6).
Analyte Spiked concentration
(ng/mL)
Extraction recovery Matrix effect
Mean (%) RSD (%) Mean (%) RSD (%)
FA 0.595 89.2 5.9 94.0 2.6
2.98 87.0 7.0 97.2 5.8
15.9 88.4 2.7 108.7 4.1
5-M-THF 12.1 88.8 2.9 100.6 5.0
21.2 91.1 3.1 100.9 4.8
42.4 89.3 2.6 101.6 4.9
IS 2.51 83.4 3.9 102.9 4.5
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bration curve that can be measured with acceptable accuracy and
precision. The LLOQ was established using ﬁve samples in-
dependent of the standards and the intra- and inter-day precision
(%RSD) which should not exceed 20% and the accuracy (%RE)
should be within 720%.
The extraction recovery (expressed as R) and the matrix effect
(expressed as ME) of FA and 5-M-THF were determined by ana-
lyzing six replicates of QC samples at three concentration levels. R
was calculated by comparing the peak areas obtained from the
peak areas of extracted spiked samples (deﬁned as A) subtracting
those of the extracted blank human samples (deﬁned as A0) with
the peak areas obtained from the peak areas of analytes spiked
post-extraction (deﬁned as B) subtracting A0, R¼(AA0)/
(BA0)100%. ME was evaluated by comparing the peak areas
obtained from B subtracting A0 with the mean peak area of the
neat standard solutions of the analytes (deﬁned as C),
ME¼(BA0)/C100%. The extraction recovery and matrix effect
of the IS were evaluated in the same procedure, but A0 of IS was
zero.
The stability of FA and 5-M-THF in plasma containing
100 mg/mL of 2-mercaptoethanol under different storage condi-
tions was evaluated by QC samples at low and high concentration
levels in three replicates, including after being kept at room
temperature for 7.5 h, stored at 80 °C for 50 days, and analyzed
after three freeze-thaw cycles. The supernatant stability test was
conducted by reanalyzing QC samples at low and high con-
centration levels kept under autosampler (4 °C) for 10 h, at room
temperature for 12 h and at 80 °C for 24 h.
2.6. Pharmacokinetic study
A pharmacokinetic study was performed in 20 healthy Chinese
male volunteers approved by the Ethics Committee of the Second
Afﬁliated Hospital of Soochow University (Suzhou, China). Thereference of the protocol is No. 2011L01475. All the volunteers
were recruited after thorough medical, biochemical and physical
examinations and were given written informed consent to parti-
cipate in the study according to the principles of the Declaration of
Helsink. During the experiment, subjects consumed an identical
and specially- prepared low-folate diet boiled at least for 1 h to
eliminate the folates in foods.
To minimize the inter-individual differences of FA 5-M-THF
baseline levels in the volunteers, a presaturation regimen with FA
was followed. The volunteers were fasted overnight (10 h) and
given an FA tablet (containing 5 mg FA) at 7:00 a.m. and then ate
breakfast at 8:00 a.m. for four consecutive days, followed by three
FA-free days (without the treatment of FA tablet). Then, the vo-
lunteers fasted overnight (10 h) and were administered two FA
tablets (0.4 mg2) at 7:00 a.m. on the eighth day. Blood samples
(4 mL) were collected into heparin tubes at 0, 0.167, 0.333, 0.667, 1,
1.5, 2, 2.5, 3, 3.5, 4 (before lunch), 5, 6, 8, 10, 12 (before supper) and
24 h after administration of drugs. Plasma was separated from the
blood by centrifugation at 2005g at 4 °C for 5 min. Aliquot of 50 mL
of 10 mg/mL of 2-mercaptoethanol was added to each milliliter
separated plasma sample immediately and vortex-mixed for 10 s.
Plasma samples were frozen at 80 °C until analysis. There is no
circadian variation in folate baseline in human; thus the baseline
concentration was only assessed by the plasma sample collected
before drug administration. The baseline concentrations of the
analytes should be subtracted when calculating their pharmaco-
kinetic parameters.3. Results and discussion
3.1. Stability studies
Folates are known to be degradable compounds that are sensi-
tive to heat, pH, oxygen and light. For unstable analytes, the greatest
challenge is how to keep them stable before and during analysis
[27]. De Brouwer et al. [13] reported that FA and 5-M-THF were
relatively stable at different pH values (from 2 to 10) with and
without heat treatment in phosphate buffer containing 1% ascorbic
acid and 2% 2-mercaptoethanol. Kirsch [23] found that FA and 5-M-
THF were stable at 4 °C over 24 h in aqueous solutions with or
without ascorbic acid at different pH values. Nevertheless, the
composition of the plasma was more complex than aqueous solu-
tions. In our study, the stability of FA and 5-M-THF in plasma was
investigated at room temperature (about 20 °C) over 24 h without
or with 2-mercaptoethanol at three concentration levels (1, 10
and 100 μg/mL). It was clearly observed that FA and 5-M-THF in
plasma degraded faster without 2-mercaptoethanol than with
2-mercaptoethanol, and FA was stable in plasma with 1 μg/mL of
Table 3
Stability of FA and 5-M-THF in plasma under different storage conditions (n¼3).
Storage conditions Analytes Concentration levels (ng/mL) RSD (%) RE (%)
Nominal Determined
FA 0.595 0.580 4.7 2.6
Residue stability 15.9 16.5 1.4 3.9
(1 h, room temperature) 5-M-THF 12.1 13.2 1.4 8.8
42.4 46.3 1.1 9.1
FA 0.595 0.637 6.2 7.1
Short-term stability 15.9 16.7 3.2 5.3
(7.5 h, room temperature) 5-M-THF 12.1 12.4 0.6 2.1
42.4 44.2 1.3 4.3
FA 0.595 0.587 6.4 1.4
Freeze/thaw stability 15.9 14.8 0.5 7.2
(three cycles) 5-M-THF 12.1 12.8 4.5 5.2
42.4 46.0 5.0 8.3
FA 0.595 0.658 6.8 10.6
Long-term stability 15.9 16.9 4.1 6.3
(50 days, 80 °C) 5-M-THF 12.1 10.8 2.6 10.8
42.4 41.2 4.6 2.9
FA 0.595 0.617 6.7 3.8
Autosampler stability 15.9 17.2 2.9 8.1
(10 h, 4 °C) 5-M-THF 12.1 12.3 7.8 1.5
42.4 43.1 0.8 1.6
FA 0.595 0.566 6.1 4.9
Supernatant stability 15.9 16.6 7.9 4.5
(12 h, room temperature) 5-M-THF 12.1 13.0 1.9 7.6
42.4 46.4 3.5 9.4
FA 0.595 0.580 3.5 2.6
Supernatant stability 15.9 14.8 4.2 2.0
(24 h, 80 °C) 5-M-THF 12.1 12.3 6.4 1.2
42.4 44.8 3.0 5.6
Table 4
Pharmacokinetic parameters of FA and 5-M-THF (mean7SD) in 20 healthy Chinese
male volunteers after an oral administration of 0.8 mg folic acid.
Parameters FA 5-M-THF
AUC0t (ng/mL h) 14.676.6 121.4762.5
Cmax (ng/mL) 5.3872.14 15.778.0
Tmax (h) 2.771.4 4.473.5
t1/2 (h) 1.471.5 5.677.5
AUC0t: area under the plasma mean concentrations–time curve from zero to t. For
FA t¼12 h and for 5-M-THF t¼24 h.
Cmax: peak concentration in plasma.
Tmax: time to peak concentration.
t1/2: half-life of drug elimination during the terminal phase.
Fig. 4. Mean plasma concentration-time proﬁles (mean7SD, baseline values cor-
rected) of FA and 5-M-THF in human plasma after an oral administration of 0.8 mg
ofb folic acid (n¼20).
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concentration of 2-mercaptoethanol in plasma was increased to
100 μg/mL (Fig. 2B). According to our investigation and in ac-
cordance with previous study [18], FA and 5-M-THF degraded in
acidic conditions but stayed stable in neutral and basic conditions atroom temperature. Moreover, it was also found that 5-M-THF de-
graded fast in dried residue at room temperature because of the
absence of 2-mercaptoethanol. Thus several disposal methods such
as adding 2-mercaptoethanol as a single antioxidant; keeping at a
non-acid condition as well as avoiding light should be taken into
consideration to avoid the degradation of FA and 5-M-THF during
all the sample preparation period. As a result, we optimized the
precipitant (methanol) and the reconstitution ﬂuid (acetonitrile:
5 mM ammonium acetate, 11:89, v/v) by adding 10 mg/mL of
2-mercaptoethanol and 0.025% (v/v) ammonium hydroxide. At the
same time, the sample preparation was carried out under dim light.
All these disposal methods guaranteed the stability of FA and 5-M-
THF during pretreatment and ensured the accurate quantitation of
them to some extent.
X.-H. Zheng et al. / Journal of Pharmaceutical Analysis 5 (2015) 269–2752743.2. Method development
Most of the reported procedures [21–24] have applied SPE
(using C18 solid-phase extraction cartridges or ion exchange and
mixed mode solid-phase extraction cartridges) for plasma ex-
traction for the analysis of FA. Instead of SPE, our sample pre-
paration required methanol precipitation followed by drying.
2-Mercaptoethanol was used as an antioxidant added into the
plasma sample prior to the sample preparation and it was also
added into methanol and reconstitution ﬂuid in the preparation
procedure. The speciﬁc measures were: (i) after the plasma was
separated from the blood, aliquot of 50 mL of 10 mg/mL of
2-mercaptoethanol was added to each milliliter separated plasma
sample immediately; (ii) the methanol solution and the recon-
stituted ﬂuid both contained 10 mg/mL of 2-mercaptoethanol so
that the post-preparation samples contained 2-mercaptoethanol.
This relative simple and rapid sample handling procedure met the
sensitivity requirement with minimal degradation of the highly
unstable folates. As for the MS condition, detection with the po-
sitive ionization mode was found to produce a better response
than that with the negative ionization mode. As for the chroma-
tographic condition, acetonitrile was preferred to methanol as it
gave a better peak shape. At the same time, the addition of 0.6%
formic acid in the aqueous portion of the mobile phase produced
more symmetrical peaks and much higher mass spectrometric
response for FA and 5-M-THF. Meanwhile, 1 mM of ammonium
acetate was added into the aqueous portion of the mobile phase,
too. The buffer solution containing 0.6% formic acid and 1 mM of
ammonium acetate helped to stabilize the mobile phase pH and
improve the peak shapes of the analytes. In order to eliminate the
matrix effect, a gradient elution system was performed and each
chromatographic run was completed within 10.0 min.
3.3. Assay validation
3.3.1. Selectivity
Fig. 3 shows the typical chromatograms of blank plasma, LLOQ
for FA and 5-M-THF, and the plasma sample from a volunteer after
an oral administration. The retention time of FA, 5-M-THF and the
IS was 2.71, 1.30 and 1.83 min, respectively. No signiﬁcant inter-
ference in the blank plasma samples was observed at the retention
time of the IS.
3.3.2. Calibration curve
Calibration curves were linear over the concentration ranges of
0.249–19.9 ng/mL for FA with correlation coefﬁcient rZ0.999, and
5.05–50.5 ng/mL for 5-M-THF with correlation coefﬁcient
rZ0.996. The typical equations of the calibration curves were:
f’¼0.179Cþ0.00869 for FA and f’¼0.0925Cþ0.0139 for 5-M-THF.
3.3.3. Accuracy and precision
Table 1 summarizes the precision and accuracy for the analysis
of FA and 5-M-THF in human plasma (n¼15) evaluated by assaying
the LLOQ and QC samples.
3.3.4. Extraction recovery and matrix effects
The extraction recovery and matrix effect results of the analytes
are shown in Table 2. These data indicated that the sample pre-
paration method was proved to be successful and the coeluting
matrix components had no appreciable matrix effect on the
analytes.
3.3.5. Stability
The stability of FA and 5-M-THF in plasma was studied under a
variety of storage conditions. The results are shown in Table 3. FA
and 5-M-THF were proved to be stable under the test conditions.3.4. Pharmacokinetics study
This validated LC–MS/MS method was successfully applied to a
pharmacokinetic study of FA and 5-M-THF in 20 healthy Chinese
male volunteers after an oral administration of 0.8 mg of FA. The
mean plasma concentrations–time proﬁles of FA and 5-M-THF are
presented in Fig. 4 and the pharmacokinetic parameters are pre-
sented in Table 4.4. Conclusion
A relative simple and reproducible LC–MS/MS method for
the simultaneous determination of FA and 5-M-THF in human
plasma has been developed and validated. Instead of SPE, the
method of protein precipitation has a lot of advantages, such as
simplifying the sample preparation, increasing the speed of sam-
ple preparation and minimizing the degradation of FA and 5-M-
THF. Meanwhile, the addition of antioxidant 2-mercaptoethanol,
the non-acid condition and the immediate reconstitution during
the sample preparation can effectively ensure the stability of FA
and 5-M-THF. The developed method has been successfully ap-
plied to the pharmacokinetic study of FA and 5-M-THF in healthy
Chinese male volunteers.References
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